Arbuckle Stuart A — SEC Form 4 filings
SEC reporting owner CIK 1557290. 24 Form 4 filings on record with FilingPulse; latest filed 2026-06-25.
Transaction summary — filings shown
Covers all 24 filings on record, filed 2024-02-08 to 2026-06-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 5 filings — 17,805 shares, $7,518,751 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 47.
- Largest priced transaction: sale of 5,034 shares @ $425.70 ($2,142,974) in VERTEX PHARMACEUTICALS INC / MA, filed 2024-02-27.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, COO | 14 | — | 5 legs · 17,805 sh · $7,518,751 | 16 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | Director | 5 | — | — | 12 |
| ImmunoGen, Inc. (IMGN) | Director | 1 | — | — | 11 |
| Praxis Precision Medicines, Inc. (PRAX) | Director | 2 | — | — | 5 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Director | 2 | — | — | 3 |
Form 4 filings — Arbuckle Stuart A
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-25 | 4 | RHYTHM PHARMACEUTICALS, INC. (RYTM) | Option exercise (M): 4,712 · Option exercise (M): 4,712 (derivative) @ $0 · Grant/award (A): 3,691 (derivative) @ $0 · Grant/award (A): 2,324 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Praxis Precision Medicines, Inc. (PRAX) | Grant/award (A): 1,371 @ $0 · Grant/award (A): 648 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 671 @ $0 · Grant/award (A): 1,441 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Praxis Precision Medicines, Inc. (PRAX) | Grant/award (A): 688 @ $0 · Grant/award (A): 478 @ $0 · Grant/award (A): 224 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,279 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 37,243 @ $450.23 | EDGAR |
| 2025-06-26 | 4 | RHYTHM PHARMACEUTICALS, INC. (RYTM) | Grant/award (A): 7,037 (derivative) @ $0 · Grant/award (A): 4,712 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | RHYTHM PHARMACEUTICALS, INC. (RYTM) | Option exercise (M): 4,000 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 37,622 @ $0 | EDGAR |
| 2025-02-28 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 7,071 @ $479.61 | EDGAR |
| 2025-02-26 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 4,716 @ $483.28 | EDGAR |
| 2025-02-19 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 2,724 @ $463.46 | EDGAR |
| 2025-02-14 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 7,903 @ $0 | EDGAR |
| 2025-02-12 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 3,220 @ $467.98 | EDGAR |
| 2025-02-06 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 14,624 @ $0 · Grant/award (A): 8,448 @ $0 | EDGAR |
| 2024-06-25 | 4 | RHYTHM PHARMACEUTICALS, INC. (RYTM) | Option exercise (M): 3,000 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | RHYTHM PHARMACEUTICALS, INC. (RYTM) | Grant/award (A): 14,000 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 69 @ $430.93 | EDGAR |
| 2024-02-27 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 4,714 @ $431.79 · Sale (S): 5,034 @ $425.70 | EDGAR |
| 2024-02-23 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 3,603 @ $421.77 | EDGAR |
| 2024-02-21 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 4,499 @ $424.01 · Tax withholding (F): 3,373 @ $420.58 · Sale (S): 4,804 @ $420.79 | EDGAR |
| 2024-02-13 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 3,177 @ $422.74 · Sale (S): 4,295 @ $420.24 | EDGAR |
| 2024-02-12 | 4 | ImmunoGen, Inc. (IMGN) | Disposition to issuer (D): 5,381 · Disposition to issuer (D): 13,090 (derivative) · Disposition to issuer (D): 63,000 (derivative) · Disposition to issuer (D): 4,167 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 15,800 (derivative) · +5 more | EDGAR |
| 2024-02-08 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 6,976 @ $0 · Grant/award (A): 11,210 @ $0 · Grant/award (A): 8,448 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1557290 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →